Amneal Pharmaceuticals
NasdaqGS:AMRX Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
AN
Consensus Narrative from 4 Analysts
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
Key Takeaways The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth. Strong performance in injectables and AvKARE segments underpins diversified revenue and enhances top-line growth and profitability.
View narrativeUS$11.50
FV
22.7% undervalued intrinsic discount7.40%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
3 days ago author updated this narrative